Sign In

Article Information

  • FDAs Oversight of the Promotion of Drugs for Off-Label Uses

    The Government Accountability Office, GAO, which you may be familiar with, is the investigative arm of Congress and most of our work comes at the request of members of Congress. In July of last year we issued a report on the FDA’s oversight of the promotion of drugs for off-label uses. The report originated as a request from Senator Grassley, a Senator from Iowa who is very interested in FDA issues, and who was then the Chair of the Senate Finance Committee.